Ovid Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	13.15	26.3	27.04	44.87	187.8
Short-Term Investments	56.48	26.77	78.79	84.13	-
Cash & Short-Term Investments	69.64	53.08	105.83	129	187.8
Cash Growth	31.20%	-49.85%	-17.96%	-31.31%	160.71%
Other Current Assets	4.73	2.87	3.76	2.38	2.68
Total Current Assets	74.37	55.94	109.6	131.38	190.48
Net Property, Plant & Equipment	11.86	13.23	14.66	16.07	0.24
Long-Term Investments	62.77	20.97	17.63	5.62	1.63
Other Long-Term Assets	1.93	2.02	2.14	2.19	2.19
Total Assets	150.93	92.17	144.03	155.27	194.54
Accounts Payable	1.96	3.19	3.7	1.95	7.13
Accrued Expenses	4.9	5.99	6.52	4.5	7.67
Current Portion of Leases	1.43	1.34	1.25	0.53	-
Total Current Liabilities	8.29	10.52	11.47	6.99	14.8
Long-Term Leases	11.99	13.42	14.76	16	-
Other Long-Term Liabilities	-	-	30	-	-
Total Long-Term Liabilities	11.99	13.42	44.76	16	-
Total Liabilities	20.27	23.94	56.23	22.99	14.8
Preferred Stock	-	-	-	0	0
Common Stock	0.13	0.07	0.07	0.07	0.07
Additional Paid-in Capital	452.45	372.49	365.59	357.77	351.03
Accumulated Other Comprehensive Income	-0.2	-0.04	0	-0.04	-
Retained Earnings	-321.71	-304.3	-277.87	-225.53	-171.36
Shareholders' Equity	130.66	68.23	87.8	132.27	179.75
Total Liabilities & Equity	150.93	92.17	144.03	155.27	194.54
Total Debt	13.42	14.76	16	16.54	0
Net Cash (Debt)	56.22	38.32	89.83	112.47	187.8
Net Cash Growth	46.70%	-57.34%	-20.13%	-40.11%	160.71%
Net Cash Per Share	0.76	0.54	1.27	1.60	2.76
Book Value	130.66	68.23	87.8	132.27	179.75
Book Value Per Share	1.77	0.96	1.24	1.88	2.64
Tangible Book Value	130.66	68.23	87.8	132.27	179.75
Tangible Book Value Per Share	1.77	0.96	1.24	1.88	2.64

Updated Mar 18, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q